TRIZIVIR

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug TRIZIVIR contains a combination of these active pharmaceutical ingredients (APIs):

1	Abacavir UNII J220T4J9Q2 - ABACAVIR SULFATE
	Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle.
	Read more about Abacavir
2	Lamivudine UNII 2T8Q726O95 - LAMIVUDINE
	Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.
	Read more about Lamivudine
3	Zidovudine UNII 4B9XT59T7S - ZIDOVUDINE
	Zidovudine is an antiviral agent which is highly active in vitro against retroviruses including the Human Immunodeficiency Virus (HIV).
	Read more about Zidovudine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TRIZIVIR Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AR04	Zidovudine, lamivudine and abacavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10305J
EE	Ravimiamet	1110980
ES	Centro de información online de medicamentos de la AEMPS	100156004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	435748
FR	Base de données publique des médicaments	64976070
GB	Medicines & Healthcare Products Regulatory Agency	44192
HK	Department of Health Drug Office	49277
IT	Agenzia del Farmaco	034947010, 034947022, 034947034, 034947046
LT	Valstybinė vaistų kontrolės tarnyba	1007906, 1031458, 1055422, 1056594
NL	Z-Index G-Standaard, PRK	136026
PL	Rejestru Produktów Leczniczych	100110487
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65016001, W65016002
US	FDA, National Drug Code	49702-217